Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.03

— 0.00 (0.00)

As at 25/04/2024

Market capitalisation: AUD68m

View equity

Flash note

Healthcare

16.04.24

Actinogen Medical — First patient dosed in Phase IIb XanaMIA study

Update

Healthcare

29.02.24

Actinogen Medical — Pressing forward with Xanamem

thematic

Healthcare

04.01.24

NZD3.07

▾ −0.06 (−1.92)

As at 25/04/2024

Market capitalisation: NZD322m

View equity

Flash note

Healthcare

05.03.24

AFT Pharmaceuticals — Poised for international market expansion

Update

Healthcare

19.02.24

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Flash note

Healthcare

08.02.24

CHF40.55

▾ −0.70 (−1.70)

As at 25/04/2024

Market capitalisation: CHF532m

View equity

Update

Healthcare

22.04.24

Basilea Pharmaceutica — Need for innovation against severe infections

Flash note

Healthcare

10.04.24

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Update

Healthcare

04.04.24

USD0.75

▾ −0.06 (−7.18)

As at 25/04/2024

Market capitalisation: USD4m

View equity

Update

Healthcare

26.04.24

Biodexa Pharmaceuticals — In a period of transition

Update

Healthcare

31.01.24

Biodexa Pharmaceuticals — Foray into T1D expands business scope

thematic

Healthcare

04.01.24

SEK3.57

▾ −0.13 (−3.51)

As at 25/04/2024

Market capitalisation: SEK656m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK4.07

▾ −0.06 (−1.45)

As at 25/04/2024

Market capitalisation: SEK1,143m

View equity

Flash note

Healthcare

16.04.24

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

edison tv

Healthcare

26.02.24

Cereno Scientific – Executive interview with CSO and CMO

edison tv

Healthcare

22.02.24

SEK1.05

▾ 0.14 (15.38)

As at 25/04/2024

Market capitalisation: SEK68m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.35

▾ 0.35 (1.01)

As at 25/04/2024

Market capitalisation: GBP127m

View equity

Flash note

Healthcare

25.04.24

Creo Medical — NHS data validates Speedboat’s economic merit

Flash note

Healthcare

04.03.24

Creo Medical — MicroBlate Flex progresses with first robotics use

Flash note

Healthcare

08.02.24

USD2.13

▾ −0.17 (−7.39)

As at 25/04/2024

Market capitalisation: USD57m

View equity

Update

Healthcare

03.04.24

Immix Biopharma — Reaffirmed long-term focus on outpatient CAR-T

Flash note

Healthcare

26.03.24

Immix Biopharma — Marching towards US clinical trials for NXC-201

Flash note

Healthcare

27.02.24

SEK10.55

▾ −0.95 (−8.26)

As at 25/04/2024

Market capitalisation: SEK547m

View equity

Update

Healthcare

09.04.24

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis

Flash note

Healthcare

25.03.24

IRLAB Therapeutics — FDA thumbs up to mesdopetam’s Phase III plan

Flash note

Healthcare

20.03.24

EUR1.59

▾ −0.10 (−6.03)

As at 25/04/2024

Market capitalisation: EUR47m

View equity

Mendus (IMMU)

Latest price

SEK0.49

▾ −0.01 (−2.00)

As at 25/04/2024

Market capitalisation: SEK494m

View equity

Flash note

Healthcare

04.04.24

Mendus — Gross proceeds of c SEK69m to advance pipeline

Flash note

Healthcare

28.03.24

Mendus — Regulatory green light for CADENCE trial

Flash note

Healthcare

13.03.24

USD8.46

▾ −0.41 (−4.62)

As at 25/04/2024

Market capitalisation: USD595m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

edison tv

Healthcare

20.04.23

MindMed update on major depressive disorder data: Rob Barrow, CEO

edison tv

Healthcare

29.03.23

CHF7.00

— 0.00 (0.00)

As at 25/04/2024

Market capitalisation: CHF131m

View equity

Update

Healthcare

20.03.24

Newron Pharmaceuticals — Evenamide set for a pivotal year

Flash note

Healthcare

15.03.24

Newron Pharmaceuticals — Operational flexibility with new/updated financing

Update

Healthcare

05.01.24

EUR0.38

— 0.00 (0.26)

As at 25/04/2024

Market capitalisation: EUR20m

View equity

Flash note

Healthcare

18.12.23

Nicox — Animal data show favourable profile vs Lumigan

Update

Healthcare

14.11.23

Nicox — Q323 update confirms trajectory for NCX-470

Flash note

Healthcare

21.07.23

USD0.56

▾ −0.05 (−8.16)

As at 25/04/2024

Market capitalisation: USD6m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.03

Actinogen Medical — First patient dosed in Phase IIb XanaMIA study

Actinogen Medical — Pressing forward with Xanamem

Outlook for 2024: Life sciences – where has the conviction gone?

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.07

AFT Pharmaceuticals — Poised for international market expansion

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF40.55

Basilea Pharmaceutica — Need for innovation against severe infections

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

See morecontent on

Biodexa Pharmaceuticals (BDRX)

USD0.75

Biodexa Pharmaceuticals — In a period of transition

Biodexa Pharmaceuticals — Foray into T1D expands business scope

Outlook for 2024: Life sciences – where has the conviction gone?

See morecontent on

Cantargia (CANTA)

SEK3.57

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK4.07

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Cereno Scientific – Executive interview with CSO and CMO

Cereno Scientific – executive interview

See morecontent on

Chosa (CHOSA)

SEK1.05

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.35

Creo Medical — NHS data validates Speedboat’s economic merit

Creo Medical — MicroBlate Flex progresses with first robotics use

Creo Medical — Solid FY23 lays the groundwork for 2024

See morecontent on

Immix Biopharma (IMMX)

USD2.13

Immix Biopharma — Reaffirmed long-term focus on outpatient CAR-T

Immix Biopharma — Marching towards US clinical trials for NXC-201

Immix Biopharma — 2023 recap with a preview of active year ahead

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK10.55

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis

IRLAB Therapeutics — FDA thumbs up to mesdopetam’s Phase III plan

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on